A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…
We present the case of a female in her 20s with a history of obesity and obstructive sleep apnea (OSA) on continuous positive airway pressure (CPAP) therapy, who developed silent microaspiration pneumonitis and organising pneumonia (OP) following the…
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independe…
BACKGROUND: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, for weight management has raised new considerations in aesthetic surgery. While these drugs offer significant preoperative weight loss benefits,…
BACKGROUND: Idiopathic intracranial hypertension (IIH) is a neurological condition marked by elevated intracranial pressure (ICP) with no evident secondary cause, primarily affecting obese females of childbearing age. While acetazolamide is the stand…
BACKGROUND: Semaglutide 2.4 mg benefits weight loss and reduction of cardiovascular disease (CVD) risk factors in adults with obesity. We estimated the US population eligibility for semaglutide 2.4 mg (based on the weight management indication) and t…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasing in prevalence as the "go-to" medication for type 2 diabetes, obesity, and off-label weight loss. The changes associated with the use of these medications can result in an…
The 2024 ESC Guidelines for the management of chronic coronary syndromes expand the concept of CCS (chronic coronary syndrome), adopting a broader vision that includes structural and functional alterations throughout the coronary tree. A significant…
IMPORTANCE: Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction and cardiovascular benefits in clinical trials. However, its association with clinical outcomes and health care expenditures remains un…
BACKGROUND: GLP-1 medicines (e.g. Semaglutide; Tirzepatide) are diabetes medicines that have recently been approved for weight loss purposes. These drugs are increasingly common, with many users accessing these medicines for off-label lifestyle-orien…
BACKGROUND: Whether patients with chronic ankle instability (CAI) can benefit from weight loss yielded by using glucagon-like peptide-1 receptor agonists (GLP1-RAs) has remained unclear. METHODS: In this observational study, we recruited more than 20…
Familial partial lipodystrophy (FPLD) is a rare genetic disorder leading to adipose tissue deficiency/redistribution and metabolic dysregulation with insulin resistance, diabetes mellitus, and dyslipidemia. Coincidence of FPLD and autoantibody-positi…
The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigationa…
GIM/FP/GP: [Formula: see text] Gastroenterology: [Formula: see text].
The rise of compounded weight-loss drugs has emerged as a pressing global health issue, threatening consumers and health-care systems. Factors fueling this crisis include the desire for rapid weight-loss options, inadequate regulatory frameworks, and…
The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone gluc…